Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Cancer Survivors
Interventions: Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions: PEN-221; Drug
Lead sponsor: Tarveda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more

Conditions: Influenza, COVID-19, Common Cold
Interventions: Immune Support Supplement; Dietary Supplement
Lead sponsor: Center For Interventional Pain and Spine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Heart Failure, Volume Overload
Interventions: Direct Sodium Removal Infusate 2.0; Drug
Lead sponsor: Sequana Medical N.V.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions: ONC201, Radiation Therapy, Paxalisib, DNX-2401; Drug · Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years to 39 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more

Conditions: Elective Surgery
Interventions: Alertwatch - Interaction; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Liver Transplant, Hepatitis C
Interventions: Pegasys, Copegus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Wichita, Kansas • Bloomington, Minnesota + 7 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, mRNA-1647; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Peoria, Illinois • Lenexa, Kansas • Lexington, Kentucky + 3 more

Conditions: Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
Interventions: Fruquintinib, Tislelizumab; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more

Conditions: Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome, CLOVES Syndrome, Blue Rubber Bleb Nevus Syndrome
Interventions: High Intensity focused ultrasound; Device
Lead sponsor: Sonablate; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Darien, Connecticut

Conditions: Duchenne Muscular Dystrophy
Interventions: Delandistrogene Moxeparvovec, Standard of Care; Genetic · Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 26 more

Conditions: COPD Exacerbation
Interventions: RespirAI; Device
Lead sponsor: RespirAI US Inc; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Wound Heal
Interventions: innovaMatrix AC; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Paget's Disease of Bone
Interventions: Zoledronic Acid, Risedronate, Placebo to Risedronate, Placebo to Zoledronic Acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 12
States / cities: Santa Monica, California • Lakewood, Colorado • Boca Raton, Florida + 9 more

Conditions: Thyroid Eye Disease
Interventions: Observational cohort study, Batoclimab; Other · Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Osteogenesis Imperfecta (OI)
Interventions: Denosumab, Alternative osteoporosis medications; Drug
Lead sponsor: Amgen; Industry
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Indianapolis, Indiana

Conditions: Multiple Sclerosis
Interventions: Siponimod; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Female only
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: La Jolla, California

Conditions: COVID-19
Interventions: Licensed or EUA SARS-CoV-2 vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more

Conditions: Ocular Myasthenia Gravis
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Scottsdale, Arizona • Columbus, Ohio

Conditions: Cardiovascular Events, MACE
Interventions: Tezepelumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 16,640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Delirium
Interventions: ED Delirium Screening and Detection Program (ED-DDP); Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 65 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Liver Neoplasms
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more

Search by objective public record fields.

Remote Assessment of Physical Function

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Commercially Available Cannabis Products for Immune Support

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Telemedicine Control Tower for the Post-Anesthesia Care Unit

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

Early Detection of COPD Exacerbations Using Home Monitoring Device

A Retrospective, Observational Study of the Real-world Safety and Performance of InnovaMatrix® AC at a Single Centre

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Patient Registry to Evaluate the Real-world Safety of Ruconest®

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Multisite Observational Maternal and Infant Study for COVID-19

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Tezspire Cardiac Events PASS

Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)